Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.
about
Pituitary adenylate cyclase-activating polypeptide 38-mediated Rin activation requires Src and contributes to the regulation of HSP27 signaling during neuronal differentiationRANTES release contributes to the protective action of PACAP38 against sodium nitroprusside in cortical neuronsThe in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal arterySrc-dependent TrkA transactivation is required for pituitary adenylate cyclase-activating polypeptide 38-mediated Rit activation and neuronal differentiationPituitary adenylate cyclase-activating polypeptide induces translocation of its G-protein-coupled receptor into caveolin-enriched membrane microdomains, leading to enhanced cyclic AMP generation and neurite outgrowth in PC12 cellsHomology modeling and molecular docking of human pituitary adenylate cyclase‑activating polypeptide I receptor.Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Oxidative Stress in Zebrafish Hair Cells.Phosphorylation of STEF/Tiam2 by protein kinase A is critical for Rac1 activation and neurite outgrowth in dibutyryl cAMP-treated PC12D cellsChemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapiesAxotomy-induced target disconnection promotes an additional death mechanism involved in motoneuron degeneration in amyotrophic lateral sclerosis transgenic mice.Novel neuroprotective strategies in ischemic retinal lesions.Injury-associated PACAP expression in rat sensory and motor neurons is induced by endogenous BDNF.VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies.A novel cyclic AMP-dependent Epac-Rit signaling pathway contributes to PACAP38-mediated neuronal differentiationEmerging Role of PACAP as a New Potential Therapeutic Target in Major Diabetes Complications.Pituitary adenylate cyclase-activating polypeptide (PACAP) mimics neuroendocrine and behavioral manifestations of stress: Evidence for PKA-mediated expression of the corticotropin-releasing hormone (CRH) gene.Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) Pathway Is Induced by Mechanical Load and Reduces the Activity of Hedgehog Signaling in Chondrogenic Micromass Cell Cultures.Class II G protein-coupled receptors and their ligands in neuronal function and protectionAge-related decrease in cerebrovascular-derived neuroprotective proteins: effect of acetaminophenRole of PACAP in Female Fertility and Reproduction at Gonadal Level - Recent Advances.Pituitary adenylate cyclase-activating peptide induces long-lasting neuroprotection through the induction of activity-dependent signaling via the cyclic AMP response element-binding protein-regulated transcription co-activator 1.PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity.PACAP38 protects rat cortical neurons against the neurotoxicity evoked by sodium nitroprusside and thrombin.Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis.Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models.Passage through the Ocular Barriers and Beneficial Effects in Retinal Ischemia of Topical Application of PACAP1-38 in Rodents.PACAP is an endogenous protective factor-insights from PACAP-deficient mice.Effect of PACAP in central and peripheral nerve injuries.Neuropeptides and diabetic retinopathy.Distribution and protective function of pituitary adenylate cyclase-activating polypeptide in the retina.Investigation of the possible functions of PACAP in human trophoblast cells.PACAP protects against inflammatory-mediated toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease.Peptide Pharmacological Approaches to Treating Traumatic Brain Injury: a Case for Arginine-Rich Peptides.Influence of terminal differentiation and PACAP on the cytokine, chemokine, and growth factor secretion of mammary epithelial cells.PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease.Protein kinase A-dependent substance P expression by pituitary adenylate cyclase-activating polypeptide in rat sensory neuronal cell line ND7/23 cells.PACAP immunoreactivity in human malignant tumor samples and cardiac diseases.Effects of PACAP on oxidative stress-induced cell death in rat kidney and human hepatocyte cells.Pituitary adenylate cyclase-activating polypeptide is protective against oxidative stress in human retinal pigment epithelial cells.Effects of PACAP in UV-A radiation-induced retinal degeneration models in rats.
P2860
Q28115858-17AF2A92-069E-4CDA-8156-5F8F49BDA35CQ28567751-3BF17DF5-94D8-46CB-93D4-DBA732F7EA4DQ28570985-0E8FF9E5-7475-49D7-850B-76EF8606EF4DQ28583135-2A738624-334A-4D81-9CC6-3B16D44F7A89Q28584028-04560995-D4B4-411D-AF43-C8E857E9866CQ30365203-CD463FFA-9734-4722-915D-DEB56F198AB1Q30372282-3D066E4C-E4E1-43E8-881B-3B5587858345Q30500214-0DEFFCC5-B4FE-40F5-9FF9-AE1F8CE2B6D7Q33624771-55CBF500-D87E-4C58-A2F2-0778F8B06F65Q33714159-378874DA-175E-428E-B773-405BBF89EF15Q33782169-5DA5D8DA-35F4-41EC-A17F-E5EC1F0E8B0DQ33812080-2289DAEB-0DB0-4337-97AE-1201B155208BQ34788079-CA90E6A4-9D2E-4071-8C10-0870E2894D9DQ35131654-F3B09D74-48DE-45B4-BA09-16BDCC97E913Q35657065-F2F85293-7C20-4303-BCF5-94EF90A0B7C2Q35944951-FAEF4E5D-E86E-49F7-8F27-E40EADC842DAQ36088456-DB4A8C81-388D-4D99-B4D4-E65462A779B1Q36211439-E0FB8C94-36B9-4FB8-8167-C6068E173A06Q36354157-89297DD8-E822-4BC8-BB95-11EEFC4DD9D9Q36457104-0EBC6768-432F-45AF-8ACC-8031E1FA59A0Q36569944-2AFD0BD4-113E-41B6-B57F-61D0EFBB7F87Q36942673-404044C6-B6D3-48CD-8DF6-95ACCC40B3A3Q37092303-1BD85012-664C-49A7-AA3F-1A71093B2FB0Q37100959-DC694575-6BD0-4AC7-B75A-3150519A84ACQ37644437-93C0BB82-08F6-4B43-BC96-9C4488808616Q37729367-379B8E1B-FED1-4DBC-9EED-61A17562E60EQ38005003-273D10E7-5868-4444-87CC-CEB277F3250AQ38040105-CA172322-6E57-4E91-835B-0A3E7300DA70Q38050159-132AF60E-6018-4871-8422-B52EF3257EC0Q38063196-EEA0985B-5521-44D7-8031-6C3389CEA9CBQ38990442-C67D0A78-3AF1-4604-B841-A7637DE11B2CQ39003365-740B10F8-4F68-4EB3-837A-DEE14399D2C6Q39008879-E0F43B4B-B4B4-4BC2-B726-06DBD1B58C6FQ39045021-CE0732AB-2886-4325-938B-061A41F988A2Q39159132-B2800175-694E-4A49-B67F-7F162E7714E6Q39379630-676B259C-95A5-41F7-AE94-E158D9DF88A3Q39610163-FFC1E616-D77A-42E2-97D3-720204F92335Q39672838-86A64D54-3C4C-410D-B22C-D180B5F2E71EQ39678162-4B8D5091-217C-47CE-9111-622490627E88Q39867396-F10C5360-D1A2-421B-AE53-3B3892926C2E
P2860
Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.
@ast
Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.
@en
type
label
Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.
@ast
Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.
@en
prefLabel
Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.
@ast
Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.
@en
P356
P1476
Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide.
@en
P2093
Anikó Somogyvári-Vigh
Dóra Reglodi
P304
P356
10.2174/1381612043383548
P577
2004-01-01T00:00:00Z